FINDINGS
Fifty transplants performed, 30 included prophylaxis against IFIs, with
micafungin in an alternating pattern according to the previously
described protocol.
The indication for HSCT was hemoglobinopathies in 76.7%, acute leukemia
in 20.0% and Fanconi anemia in 3.3%.
The prophylaxis duration was 2.33 months (1.53 to 3.98). In our study,
40.0% (12/30) of the patients had acute GVHD, and 6.7% (2/30) had
chronic GVHD, which prolonged the duration of alternating prophylaxis.
No serious adverse effects of the use of micafungin were observed in any
of the patients. There was also no breakthrough Invasive fungal
infection (IFI) during alternating prophylaxis.
CONCLUSION: In selected patients, micafungin was well tolerated
without breakthrough IFI in our study.